Moderna Inc., US60770K1079

Moderna stock: Jefferies maintains Hold in analyst-heavy week

Published on 11/21/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock drew fresh analyst attention during the week. Jefferies kept Hold and set a 215 US dollar target, while peers retained their ratings.

Analysts focus on execution

  • Jefferies maintained a Hold rating on November 19, while Morgan Stanley and JPMorgan also kept their existing stances during the week.
  • Moderna's oncology pipeline and the planned intismeran filing remain central to the investment case.
Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Analyst actions kept Moderna in focus during the week of November 16 to 20, 2026. On November 19, Jefferies analyst Andrew Tsai maintained a Hold rating and set a 215 US dollar price target, according to Markets Insider.

The same report said Morgan Stanley analyst Terence Flynn maintained a Hold rating on November 17. JPMorgan maintained a Sell rating on November 16. The sequence left analysts focused on how quickly Moderna can convert its oncology pipeline into regulatory and commercial progress.

Oncology remains the central catalyst

Intismeran, Moderna's personalized cancer therapy developed with Merck, remains the key strategic focus. The program is moving toward a planned US regulatory filing, while additional studies in other tumor types are expected to shape the longer-term opportunity.

For investors, the analyst split highlights the execution burden around the oncology strategy. The Hold ratings point to a need for further milestones, while the Sell stance reflects a more cautious assessment of the path from clinical progress to commercial revenue.

Moderna market facts

Moderna Inc. market facts

  • Company: Moderna Inc.
  • ISIN: US60770K1079
  • Ticker: MRNA
  • Home exchange: Nasdaq
  • Latest quote: 179.39 euros on Lang & Schwarz at 11:00 CET on Saturday, November 21, 2026

Current market reports provide the broader setting for US-listed healthcare stocks.

More news and analyses on Moderna stock

Disclaimer...
en | US60770K1079 | MODERNA INC. | boerse | 70541937 | bgmi